Original from: PR Newswire Photocure ASA (OSE: PHO), the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch of a joint research initiative. The collaboration encomp..

Original from: SOPHiA GENETICS SOPHiA GENETICS (NASDAQ: SOPH) today announced that the company has signed a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer Center (MSK) relating to..

Original from: Reuters The World Health Organization chief announced a $518 million six-month ‌joint plan to fight Ebola on Friday, calling for money and political commitment to halt the spread of ..

Original from: CytoDyn Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn”), a clinical-stage oncology company advancing lero..

Original from: PR Newswire Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, today announced an expansion of its strategic collaboration with..

Agilent Technologies Inc. (NYSE: A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence (AI) across the company’s products, operations, and customer workflows.

Waters Corporation (NYSE: WAT) today announced that the BD BACTEC FXI Culture System has received U.S. Food and Drug Administration (FDA) 510(k) clearance. This clearance enables commercialization in the U.S. and provides a new option for laboratories seeking a fully automated blood culture system designed to improve the speed, consistency, and accuracy of sepsis and bloodstream infection diagnostics in modern microbiology laboratories.

QuidelOrtho, a global leader in diagnostic innovation, and the Allo Hope Foundation, a nonprofit dedicated to supporting families and clinicians managing maternal alloimmunization, announced a new collaboration focused on improving prenatal care through education, early testing and stronger connections between laboratory providers, clinicians and patients.

Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.

At present, MGT-based blood group test card has been used extensively in the field of blood typing, and MGT boasts of easy operation, high sensitivity, accurate results that can be saved and other strengthens, which a..

Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx and FoundationOne®Liquid CDx to be used as companion diagnostics for Pfizer’s TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) to identify patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). TALZENNA is first and only PARP inhibitor approved for use with an existing standard of care (XTANDI) for adult patients with both BRCA mutated and non-BRCA HRR gene-mutated mCRPC.

Canhelp Genomics Partners with Eurobio Scientific to Expand European Markets Canhelp Genomics announced the signing of a strategic partnership agreement with Eurobio Scientific, a leading European in vitr..

Original from: Natera Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology Corp., a clinical-stage biotechnolog..

Original from: Tempus Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has gr..

Original from: Agilent Second-quarter fiscal year 2026 - Revenue of $1.83 billion for the second quarter ended April 30, 2026, representing growth of 10.0% reported and up 6.3% core compared with t..